pharma · Squamous Cell Carcinoma of Head and Neck · Breast Cancer · TVRD
Tvardi Therapeutics
Tvardi Therapeutics patent portfolio — 6 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Houston, USA
- Founded
- 2017
- Employees
- 20
- Programs
- 6
- Drugs
- 2
- Patents
- 6
Tvardi Therapeutics patents
6 pharmaceutical patents indexed for Tvardi Therapeutics. 0 expire within 24 months.
Tvardi Therapeutics has 6 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12053444
Therapeutic compounds, formulations, and uses thereof
granted -
US 12043640
Prodrugs of STAT3 inhibitors
granted -
US 11826315
STAT3 inhibitors
granted -
US 11547683
Therapeutic compounds, formulations, and uses thereof
granted -
US 11077077
Therapeutic compounds, formulations, and uses thereof
granted -
US 11026905
STAT3 inhibitors
granted
Frequently asked questions
How many patents does Tvardi Therapeutics have?
6 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Tvardi Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.